CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenues:
Net product sales	$ 127,931	$ 4,427
Sanofi collaboration revenue	85,005	85,329
Bayer HealthCare collaboration revenue	12,483	12,481
Technology licensing	5,893	7,845
Contract research and other	477	2,122
Total revenues	231,789	112,204
Expenses:
Research and development	138,862	129,392
Selling, general, and admistrative	58,428	23,411
Cost of goods sold	12,298	382
Total expenses	209,588	153,185
Income (loss) from operations	22,201	(40,981)
Other income (expense):
Investment income	610	1,037
Interest expense	(11,160)	(3,719)
Total other income (expense)	(10,550)	(2,682)
Net income (loss) before income tax benefit	11,651	(43,663)
Income tax benefit		(216)
Net income (loss) - basic and diluted	11,651	(43,447)
Net income (loss) per share - basic (in dollars per share)	$ 0.12	$ (0.49)
Net income (loss) per share - diluted (in dollars per share)	$ 0.11	$ (0.49)
Weighted average shares outstanding - basic (in shares)	93,446	89,162
Weighted average shares outstanding - diluted (in shares)	107,734	89,162
Condensed Statements of Comprehensive Income (Loss)
Net income (loss) - basic and diluted	11,651	(43,447)
Other comprehensive income (loss):
Other comprehensive income, net of tax	525	316
Comprehensive income (loss)	$ 12,176	$ (43,131)